Casdin Capital 13F holdings, Q3 2022
Holdings as of September 30, 2022 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 36 US equity positions worth $1.5bn in its Q3 2022 13F filing. The largest position was EQRX INC at 12.9% of the reported book, followed by BLFS and SRPT. Against the Q2 2022 filing, it opened 6 new positions, added to 11 and reduced 8 among the top 36 holdings.
What did Casdin Capital own in Q3 2022? Top 36 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2022 |
|---|---|---|---|---|---|---|---|
| 1 | EQRX INC | 12.9% | $195.7m | 39,527,669 | 0% | held | |
| 2 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 11.4% | $172.1m | 7,566,292 | 0% | held |
| 3 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 8.9% | $135.4m | 1,225,000 | 88% | added |
| 4 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 8.6% | $129.7m | 648,000 | -20% | reduced |
| 5 | 2655787D BLUEPRINT MEDICINES CORP | 7.4% | $112.0m | 1,700,000 | 48% | added | |
| 6 | VERVE THERAPEUTICS INC | 7.2% | $109.2m | 3,178,167 | 1% | added | |
| 7 | RLAY RELAY THERAPEUTICS INC | Healthcare | 6.9% | $104.8m | 4,683,432 | 15% | added |
| 8 | ILMN ILLUMINA INC | Healthcare | 4.8% | $73.5m | 385,000 | – | new |
| 9 | MXCT MAXCYTE INC | 4.6% | $69.8m | 10,735,786 | -23% | reduced | |
| 10 | RVMD REVOLUTION MEDICINES INC | Healthcare | 3.3% | $49.7m | 2,522,300 | 6% | added |
| 11 | FATE FATE THERAPEUTICS INC | Healthcare | 3.0% | $45.9m | 2,050,000 | -2% | reduced |
| 12 | SOMALOGIC INC | 2.4% | $36.6m | 12,604,275 | 2% | added | |
| 13 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 2.1% | $31.7m | 3,206,380 | 0% | held |
| 14 | EXK EXACT SCIENCES CORP | Basic Materials | 2.1% | $31.4m | 967,000 | 115% | added |
| 15 | DNLI DENALI THERAPEUTICS INC | Healthcare | 2.0% | $30.5m | 995,000 | -34% | reduced |
| 16 | ABSI ABSCI CORPORATION | 1.6% | $24.2m | 7,718,593 | 0% | held | |
| 17 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.2% | $17.6m | 370,000 | -1% | reduced |
| 18 | MIRATI THERAPEUTICS INC | 1.2% | $17.5m | 250,000 | 158% | added | |
| 19 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 1.1% | $16.5m | 295,000 | – | new |
| 20 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 1.1% | $16.3m | 1,650,000 | 120% | added |
| 21 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 1.0% | $15.7m | 750,000 | – | new |
| 22 | WGS SEMA4 HOLDINGS CORP | 1.0% | $14.4m | 16,437,500 | 0% | held | |
| 23 | TWST TWIST BIOSCIENCE CORP | Healthcare | 0.8% | $12.9m | 365,000 | -27% | reduced |
| 24 | TNYA TENAYA THERAPEUTICS INC | 0.7% | $10.4m | 3,586,818 | 0% | held | |
| 25 | 2SEVENTY BIO INC | 0.6% | $8.9m | 614,754 | 0% | held | |
| 26 | ARVN ARVINAS INC | Healthcare | 0.6% | $8.9m | 200,000 | – | new |
| 27 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 0.3% | $4.6m | 165,000 | 0% | held |
| 28 | GLUE MONTE ROSA THERAPEUTICS INC | 0.3% | $4.2m | 510,882 | 0% | held | |
| 29 | MRNA MODERNA INC | Healthcare | 0.3% | $3.8m | 32,500 | – | new |
| 30 | SINGULAR GENOMICS SYSTEMS IN | 0.2% | $3.4m | 1,345,722 | 55% | added | |
| 31 | INVITAE CORP | 0.2% | $2.8m | 1,125,888 | 8% | added | |
| 32 | CEREVEL THERAPEUTICS HLDNG I | 0.1% | $2.3m | 80,000 | – | new | |
| 33 | EXSCIENTIA PLC | 0.1% | $1.8m | 213,900 | -68% | reduced | |
| 34 | MAGENTA THERAPEUTICS INC | 0.0% | $451.0k | 320,000 | -87% | reduced | |
| 35 | KRONOS BIO INC | 0.0% | $415.0k | 123,839 | 0% | held | |
| 36 | LIANY LIANBIO | 0.0% | $411.0k | 206,415 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.